The ACGT – Edward Netter Memorial Investigator Award in Cell and Gene Therapy for Pancreatic Cancer Research is now CLOSED.
The ACGT – Edward Netter Memorial Investigator Award in Cell and Gene Therapy for Pancreatic Cancer Research prioritizes the advancement of cell and gene therapy research to improve outcomes for pancreatic patients.
The Award will provide an investment of $500,000 dollars toward high impact research projects.
Historically, Alliance for Cancer Gene Therapy has awarded clinical translation grants of $250,000 to $500,000 over two to three years, inclusive of a maximum of 10% indirect costs. Funds may be used at the recipient’s discretion for salary, technical assistance, supplies, animals or capital equipment, but may not support staff not directly related to the project, such as secretaries or administrative assistants. Purchase of equipment is not allowed in the final year of the grant.
Applicants must hold an MD, PhD, or equivalent degree and must be tenure-track or tenured faculty. While we recognize that there may be other excellent researchers not on a tenure-track, or not at medical schools or research centers, this is an eligibility requirement for application. The investigator must be conducting original research as an independent faculty member. There are no citizenship restrictions, but research supported by the award must be conducted at academic medical centers or research centers located in the United States or Canada.
Members of our distinguished Scientific Advisory Council oversee the review and recommendation process. All Letters of Intent (LOIs) are assessed by at least two members of the Council or their approved reviewers. Applicants whose LOIs are deemed responsive to the Request for Applications (RFA) and our mission are invited to submit full applications that include: biosketch, budget, research plan (10-page max), literature citations, and letter of reference. Final applications are then carefully reviewed by the Council, which makes recommendations for final approval.
Grant funds are disbursed following execution of a grant agreement between the grantee institution and Alliance for Cancer Gene Therapy.
Applications need to be signed by an appropriate representative of the institution, such as the Signing Official for Assurances in the Grants and Contacts Department and/or in the Legal Department.
Alliance for Cancer Gene Therapy has no citizenship restrictions, but research supported by its grants must be conducted at medical schools and research centers located in the United States or in Canada.
No. In addition to the 10-page research plan, an additional four pages are allowed for literature citations.
No. Applications may be submitted only once, so please carefully read the instructions that appear throughout the application pages. If changes become necessary BEFORE the application deadline, please call Altum Proposal Central customer service at (-800) 875-2562. No changes can be made AFTER the application deadline.
Yes, please join our mailing list to receive updates about upcoming Requests for Applications.
Biotech Funding Program
Learn More About the Program“If you are creating a machine – and engineered CAR T cells are really machines – you need an on/off switch. If you have a machine with only an on switch and no off switch, you’ll get in trouble.”
Crystal Mackall, MD
Stanford University
